コーパス検索結果 (１語後でソート)
通し番号をクリックするとPubMedの該当ページを表示します
1 s an often lethal complication of allogeneic hematopoietic cell transplant.
2 1A:LLT1 (KLRB1:CLEC2D) interactions in human hematopoietic cell transplants.
3 e successful treatment of blood cancers with hematopoietic cell transplants.
4 cluding the possibility of purged autologous hematopoietic cell transplants.
5 can treat infections complicating allogeneic hematopoietic cell transplants.
6 nized by T cells in recipients of allogeneic hematopoietic cell transplants.
7 esponse to pathogens, tumors, and allogeneic hematopoietic cell transplants.
8 us-tumor effects in recipients of allogeneic hematopoietic cell transplants.
9 as limited the progress of studies involving hematopoietic cell transplants.
10 of CMV infection in recipients of allogeneic hematopoietic-cell transplants.
11 the incidence of CMV events in recipients of hematopoietic-cell transplants.
12 aspergillosis among recipients of allogeneic hematopoietic-cell transplants.
13 ses zoster and is common among recipients of hematopoietic-cell transplants.
14 ere evaluated in adults receiving allogeneic hematopoietic cell transplants (1999-2005) from HLA-iden
18 fection, based on a cohort of 237 allogeneic hematopoietic cell transplant (allo-HCT) recipients, tha
19 gene (TLR9) in a cohort of 336 recipients of hematopoietic-cell transplants and their unrelated donor
22 Patients (n = 2802) who received a first hematopoietic cell transplant between 1990 and 2002 were
25 provided a rich basis for improving clinical hematopoietic cell transplants; finding and using protei
26 Research for 1230 subjects receiving a first hematopoietic cell transplant from a human leukocyte ant
27 al history of Crohn's disease was altered by hematopoietic cell transplants from healthy allogeneic d
28 tively analyzed data from 446 patients given hematopoietic cell transplants from HLA-matched related
29 ssential thrombocythemia received allogeneic hematopoietic cell transplants from related (n = 36) or
30 syndrome who received a first myeloablative hematopoietic-cell transplant from an unrelated cord-blo
31 describe a recipient of combined kidney and hematopoietic-cell transplants from an HLA-matched donor
32 in CMV-seropositive recipients of allogeneic hematopoietic-cell transplants from matched related or u
33 tients and 263 matched controls who received hematopoietic-cell transplants from related and unrelate
34 f invasive aspergillosis among recipients of hematopoietic-cell transplants from unrelated donors.
35 isease remains a formidable challenge to the hematopoietic cell transplant (HCT) and kidney transplan
36 iagnosed before age 12 months who received a hematopoietic cell transplant (HCT) between July 1982 an
37 s obliterans syndrome (BOS) after allogeneic hematopoietic cell transplant (HCT) conferred nearly uni
38 integrated human herpesvirus 6 (ciHHV-6) in hematopoietic cell transplant (HCT) donors or recipients
39 all patients who receive an unrelated donor hematopoietic cell transplant (HCT) for the treatment of
40 ratory syncytial virus (RSV) pneumonia after hematopoietic cell transplant (HCT) is associated with s
42 nosuppressive therapy (HDIT) with autologous hematopoietic cell transplant (HCT) may, in contrast, in
43 d on the Y chromosome (HY-Abs) develop after hematopoietic cell transplant (HCT) of male recipients w
44 ) or myelodysplasia (MDS), and in allogeneic hematopoietic cell transplant (HCT) recipients (early, u
45 Records of solid organ transplant (SOT) and hematopoietic cell transplant (HCT) recipients at a sing
46 and preventing disseminated viral disease in hematopoietic cell transplant (HCT) recipients but does
47 irus (CMV) pp65-specific T cells can protect hematopoietic cell transplant (HCT) recipients from CMV
48 chromosomally integrated HHV-6 (iciHHV-6) in hematopoietic cell transplant (HCT) recipients is unclea
49 of secondary solid cancers among allogeneic hematopoietic cell transplant (HCT) recipients who recei
50 piratory samples and detection in serum from hematopoietic cell transplant (HCT) recipients with resp
58 ients with relapsed CLL following allogeneic hematopoietic cell transplant (HCT) who subsequently rec
65 ng (RIC)/nonmyeloablative (NMA) conditioning hematopoietic cell transplants (HCTs) have changed the t
66 0% to 70% of patients who receive allogeneic hematopoietic cell transplants (HCTs), and the skin is t
67 agement decisions could reduce the number of hematopoietic cell transplants in patients with AML by 2
68 ell cycle progression, and survival of human hematopoietic cells transplanted into nonobese diabetic
70 ation was present in unrelated recipients of hematopoietic-cell transplants (odds ratio, 5.00; 95% CI
73 stic leukemia (AML) who underwent autologous hematopoietic-cell transplant procedures at Stanford Uni
75 r than 12 months may be beneficial for those hematopoietic cell transplant recipients on continued im
76 hylaxis against cytomegalovirus infection in hematopoietic cell transplant recipients provided initia
77 us (VZV) disease occurs in 30% of allogeneic hematopoietic cell transplant recipients who had a histo
78 od (viremia) was detected in 9 of 79 (11.4%) hematopoietic cell transplant recipients with influenza,
79 dex (GMI) values and mortality in allogeneic hematopoietic cell transplant recipients with invasive p
80 sed risk of cutaneous malignant neoplasms in hematopoietic cell transplant recipients, this populatio
82 treatment of CMV pneumonia in recipients of hematopoietic cell transplant remains a significant chal
83 idney transplants in 3 medical centers using hematopoietic cell transplants to establish mixed or com
84 patients scheduled to receive an allogeneic hematopoietic cell transplant were randomized with their
86 ly 30% of patients who require an allogeneic hematopoietic cell transplant will have an HLA-matched s
WebLSDに未収録の専門用語（用法）は "新規対訳" から投稿できます。